Drilldown/Medicines
Use the filters below to narrow your results.
generic:
brand:
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Lithobid (lithium carbonate extended-release, 300 mg and 450 mg tablets); Lithium carbonate immediate-release tablets and capsules (150/300/600 mg; multiple generics); Lithium citrate oral solution (8 mEq/5 mL, approximately equivalent to 300 mg lithium carbonate per 5 mL). (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Orap (1) ·
Prolixin (1) ·
Saphris (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-0000004A-QINU`"' (1)
uses:
starting dose:
preparations:
fda max: (Click arrow to add another value)
onset:
None (15) ·
Oral peak plasma 1-2 hours (immediate-release); 4-6 hours (extended-release). Therapeutic antimanic effect typically evident within 5-14 days of achieving target serum levels; for acute mania, a neuroleptic or benzodiazepine is usually co-administered while lithium titration proceeds. (1)
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 16 results in range #1 to #16.